atomoxetine + placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Substance Abuse

Conditions

Substance Abuse

Trial Timeline

Jul 1, 2007 → Aug 1, 2011

NCT ID

NCT00617201

About atomoxetine + placebo

atomoxetine + placebo is a phase 2 stage product being developed by Eli Lilly for Substance Abuse. The current trial status is completed. This product is registered under clinical trial identifier NCT00617201. Target conditions include Substance Abuse.

What happened to similar drugs?

1 of 1 similar drugs in Substance Abuse were approved

Approved (1) Terminated (0) Active (0)

✅naltrexone for extended release injectable suspensionAlkermesApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (13)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00962104	Phase 3	Completed	Aug 1, 2009	Feb 1, 2011	Attention Deficit Hyperactivity Disorder
NCT00716274	Approved	Completed	Sep 1, 2008	Jul 1, 2016	Attention Deficit Hyperactivity Disorder
NCT00607919	Approved	Completed	Mar 1, 2008	Feb 1, 2011	Attention Deficit Hyperactivity Disorder
NCT00546910	Approved	Completed	Oct 1, 2007	May 1, 2009	Attention Deficit Hyperactivity Disorder
NCT00617201	Phase 2	Completed	Jul 1, 2007	Aug 1, 2011	Substance Abuse
NCT00406354	Approved	Completed	Nov 1, 2006	Jan 1, 2009	Attention Deficit Hyperactivity Disorder
NCT00380692	Approved	Completed	Oct 1, 2006	Oct 1, 2008	Autistic Disorder
NCT00260533	Phase 2/3	Completed	Nov 1, 2005	Jul 1, 2008	Generalized Social Phobia
NCT00191542	Phase 3	Completed	Mar 1, 2005	Aug 1, 2006	Attention Deficit Hyperactivity Disorder
NCT00191295	Phase 2/3	Completed	Feb 1, 2005	Sep 1, 2006	Attention Deficit Hyperactivity Disorder
NCT00190957	Approved	Completed	Aug 1, 2004	Jan 1, 2006	ADHD
NCT00386581	Phase 3	Completed	Jul 1, 2004	Feb 1, 2005	Attention Deficit Disorder With Hyperactivity
NCT00611533	Pre-clinical	Completed	May 1, 2004	Apr 1, 2008	Menopause

Competing Products

5 competing products in Substance Abuse

See all competitors

Product	Company	Stage	Hype Score
Tapentadol IR + Oxycodone IR	Johnson & Johnson	Pre-clinical	26
Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa]	Gilead Sciences	Pre-clinical	22
RDC-0313 + Buprenorphine + Placebo	Alkermes	Phase 1	26
naltrexone for extended release injectable suspension	Alkermes	Approved	40
modafinil	Pacific Biosciences	Phase 2	21